Investment Thesis
Dogwood Therapeutics is a pre-revenue biotech company with minimal commercial traction ($22.8K revenue) while burning significant cash ($15.6M operating cash outflow). With only $6.5M in cash remaining against $28M in annual operating losses, the company faces critical runway constraints and will require substantial capital raises or revenue inflection within 12-18 months to remain solvent.
Strengths
- Solid balance sheet structure with $74.9M stockholders equity and low leverage (0.00x debt/equity)
- Adequate short-term liquidity with 2.76x current ratio providing near-term operational flexibility
- Modest liabilities at $15.3M indicate limited debt obligations
Risks
- Severe cash burn rate of $15.6M annually against $6.5M cash position indicates <5 months runway
- Negligible revenue generation ($22.8K) with net losses of $34.3M demonstrates failed commercialization or pipeline maturity
- Unsustainable negative margins (operating margin -122,852%, net margin -150,476%) and negative ROE/ROA indicate core business model is not generating value
- Pre-clinical or early-stage biotech with no approved products generating meaningful revenue
- Will require significant dilutive equity financing or major clinical/regulatory success to avoid insolvency
Key Metrics to Watch
- Monthly cash burn rate and cash runway timeline
- Clinical trial progression and regulatory milestones for lead candidates
- Revenue generation from any approved or near-approval products
- Insider ownership levels and any funding announcements
- Operating expense trends relative to cash position
Financial Metrics
Revenue
22.8K
Net Income
-34.3M
EPS (Diluted)
$-7.13
Free Cash Flow
-15.6M
Total Assets
90.2M
Cash
6.5M
Profitability Ratios
Gross Margin
N/A
Operating Margin
-122,851.8%
Net Margin
-150,476.0%
ROE
-45.7%
ROA
-38.0%
FCF Margin
-68,605.2%
Balance Sheet & Liquidity
Current Ratio
2.76x
Quick Ratio
2.76x
Debt/Equity
0.00x
Debt/Assets
16.9%
Interest Coverage
N/A
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-03-23T21:52:13.336254 |
Data as of: 2025-12-31 |
Powered by Claude AI